STOCK TITAN

Newtopia Earns 5-year Recognition by CDC for Delivery of Highest Quality, Evidence-based Alternative Diabetes Prevention Program

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Newtopia Inc. has achieved the Full-Plus recognition from the CDC for its diabetes prevention program, recognizing its quality and effectiveness in combating type 2 diabetes. This designation highlights Newtopia's commitment to sustainable habit change, contributing to improved health outcomes for participants. With 96 million American adults having prediabetes, the need for effective solutions is critical. Newtopia's personalized platform combines digital technology and human interaction, showing a sustained 0.6% reduction in average A1c levels for participants. This recognition positions Newtopia as a leader in chronic disease prevention.

Positive
  • Achieved Full-Plus recognition from the CDC for its diabetes prevention program.
  • Demonstrated a 0.6% reduction in average A1c levels among participants diagnosed with type 2 diabetes.
  • Engagement rate surpasses 75% in the first year, meeting high retention criteria.
Negative
  • None.

Full-Plus CDC diabetes prevention program status awarded to Newtopia for development of sustainable healthy habits and improved disease prevention biometrics among participants

TORONTO, Sept. 20, 2022 /PRNewswire/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform creating sustainable habits that prevent, slow, and reverse chronic disease, today announced that its alternative diabetes prevention program has received the highest Full-Plus recognition from the Centers for Disease Control and Prevention (CDC). 

The CDC reserves Full-Plus designation for diabetes prevention programs that effectively deliver quality, evidence-based components that meet all CDC recognition standards as well as additional engagement and retention thresholds. This achievement acknowledges the sustained success of Newtopia's novel approach to preventing, slowing and reversing type 2 diabetes through habit change and the invaluable contribution to addressing the disease nationally.

"With 96 million American adults having prediabetes, resulting in $327 billion in medical costs, the need to successfully address type 2 diabetes with proven engagement and outcomes is immense," said Jeff Ruby, Founder and Chief Executive Officer of Newtopia.  "To have the CDC award Newtopia with its highest designation of Full-Plus and specifically note that 'Newtopia is turning the tide in the fight against the epidemic of type 2 diabetes' is truly a testament to our differentiated approach to create sustainable habit change among participants.  I could not be prouder of our team for achieving this designation and congratulate our remarkable employer and health plan clients for offering the very best disease prevention to employees and members."   

Newtopia's hyper-personalized approach combines the best of human intervention and digital technology, along with genetic engagement, to support improved health outcomes and reduced costs for employers, health plans, ACOs and other risk-bearing entities.  With Newtopia, participants are empowered to lose weight, reduce blood sugar, manage blood pressure, and lower triglycerides and cholesterol while improving their overall mental health (including depression, anxiety, mood and overall energy) to avoid future illness.  In the words of one participant, "I no longer have type 2 diabetes or take any medications to control my blood sugar.  My A1C is 5, my cholesterol is normal, and I've lost 160lbs. Newtopia has changed my life for good."    

"This recognition by the CDC is very gratifying considering type 2 diabetes continues to be a major burden of illness for 1 in 3 adults who have prediabetes, and more than 1 in 10 living with type 2 diabetes," said Dr. Natasha Vani, VP Program Development & Operations at Newtopia.  "The key to Newtopia's success lies in the engagement of our habit change program surpassing 75% in the first year. High engagement and sustainable habit change is what has allowed us to meet the strong retention criteria and required outcomes defined by the CDC, earning us the extended 5-year status.  It's no surprise that individuals in Newtopia's program who have been diagnosed with type 2 diabetes see a sustained 0.6% reduction in their average A1c, and 75% of severe cases drop a full A1c level." 

About Newtopia

Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow, or reverse chronic disease while reducing healthcare costs. The platform leverages genetic, social and behavioral insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed in Canada on the Toronto Stock Exchange (TSXV: NEWU) and is quoted in the US on the OTCQB® Venture Market (OTCQB: NEWUF). To learn more, visit newtopia.com, LinkedIn or Twitter.

Forward Looking Statements

This news release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable United States securities legislation (collectively, "forward-looking statements"), which reflects management's expectations regarding Newtopia's future growth, results from operations (including, without limitation, future production and capital expenditures), performance (both operational and financial) and business prospects and opportunities. Wherever possible, words such as "predicts", "projects", "targets", "plans", "expects", "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. All statements other than statements of historical fact may be forward- looking information. Such statements reflect Newtopia's current views and intentions with respect to future events, based on information available to Newtopia, and are subject to certain risks, uncertainties, and assumptions. Material factors or assumptions were applied in providing forward-looking information. While forward-looking statements are based on data, assumptions and analyses that Newtopia believes are reasonable under the circumstances, whether actual results, performance or developments will meet Newtopia's expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Forward-looking statements are not a guarantee and are based on a number of estimates and assumptions management believes to be relevant and reasonable, whether actual results, performance or developments will meet Newtopia's expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Certain of the "risk factors" that could cause actual results to differ materially from Newtopia's forward-looking statements in this press release include, without limitation: the termination of contracts by clients, risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters- in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; and other general economic, market and business conditions and factors, including the risk factors discussed or referred to in Newtopia's disclosure documents, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com including Newtopia's final long form prospectus dated March 30, 2020.

Should any factor affect Newtopia's in an unexpected manner, or should assumptions underlying the forward- looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Newtopia does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release, and Newtopia undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/newtopia-earns-5-year-recognition-by-cdc-for-delivery-of-highest-quality-evidence-based-alternative-diabetes-prevention-program-301627296.html

SOURCE Newtopia Inc.

FAQ

What is the significance of Newtopia receiving Full-Plus recognition from the CDC?

The Full-Plus recognition signifies that Newtopia's diabetes prevention program meets high quality standards set by the CDC, indicating its effectiveness and sustained success in combating type 2 diabetes.

How does Newtopia's diabetes prevention program impact participants' health outcomes?

Participants in Newtopia's program achieve an average 0.6% reduction in A1c levels, indicating improved blood sugar control and overall health benefits.

What percentage of participants engage with Newtopia's diabetes prevention program?

Newtopia reports an engagement rate exceeding 75% within the first year of participation, which is critical for meeting retention and outcome criteria.

What company ticker symbol represents Newtopia in the stock market?

Newtopia is represented by the ticker symbols TSXV: NEWU and OTCQB: NEWUF.

NEWTOPIA INC

OTC:NEWUF

NEWUF Rankings

NEWUF Latest News

NEWUF Stock Data

2.84M
134.05M
13.05%
0.8%
Health Information Services
Healthcare
Link
United States of America
Toronto